Chromium

Pronunciation: (KROE-mee-uhm)Class: Trace Metal

Trade Names:Chromic Chloride- Injection 4 mcg/mL (as 20.5 mcg chromic chloride hexahydrate)- Injection 20 mcg/mL (as 102.5 mcg chromic chloride hexahydrate)

Trade Names:Chromium Chloride- Injection 4 mcg/mL (as 20.5 mcg chromic chloride hexahydrate)

Trade Names:Chroma-Pak- Injection 4 mcg/mL (as 20.5 mcg chromic chloride hexahydrate)- Injection 20 mcg/mL (as 102.5 mcg chromic chloride hexahydrate)

Pharmacology

Helps maintain normal glucose metabolism and peripheral nerve function.

Pharmacokinetics

Absorption

Typical blood levels range from 1 to 5 mcg/L.

Elimination

Primarily via the kidney.

Indications and Usage

Use as a supplement to IV solutions given for total parenteral nutrition (TPN) to prevent depletion of endogenous stores and subsequent deficiency symptoms.

Contraindications

Direct IM or IV injection.

Dosage and Administration

Trace Metal for TPNAdults

TPN Additive 10 to 15 mcg/day. Metabolically stable adults with intestinal fluid loss may require 20 mcg/day.

Children

TPN Additive 0.14 to 0.20 mcg/kg/day.

General Advice

• For admixture in TPN solution only. Not for intradermal, subcutaneous, IM, or direct IV administration.
• Do not administer if particulate matter, cloudiness, or discoloration are noted.
• Discard any unused solution in the single-dose vial. Do not save for future use.

Storage/Stability

Store vials at controlled room temperature (59° to 86°F).

Drug Interactions

None well documented.

Laboratory Test Interactions

None well documented.

Adverse Reactions

None known.

Precautions

Pregnancy

Category C .

Lactation

Undetermined.

Children

Safety and efficacy not established (see Route/Dosage).

Renal Function

Dosage may need to be adjusted or omitted.

General

Use only in conjunction with a pharmacy-directed admixture program using aseptic technique in a laminar flow environment.

Overdosage

Symptoms

Nausea, vomiting, GI ulcers, renal and hepatic damage, convulsions, coma.

Patient Information

• Advise patient, family, or caregiver that medication will be added to TPN solution.
• Advise patient to report pain, redness, warmth, or swelling of TPN access site.

Copyright © 2009 Wolters Kluwer Health.

• chromium picolinate Concise Consumer Information (Cerner Multum)
• Chromium Picolinate MedFacts Consumer Leaflet (Wolters Kluwer)